{"organizations": [], "uuid": "67a08afb09b64b24de8be4b4ad3d7959625be599", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-protalix-announces-positive-result/brief-protalix-announces-positive-results-from-phase-ii-clinical-trial-of-oprx-106-for-treatment-of-ulcerative-colitis-idUSASC09RYF", "country": "US", "domain_rank": 408, "title": "BRIEF-Protalix Announces Positive Results From Phase II Clinical Trial Of OPRX-106 For Treatment Of Ulcerative Colitis", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-13T13:11:00.000+02:00", "replies_count": 0, "uuid": "67a08afb09b64b24de8be4b4ad3d7959625be599"}, "author": "", "url": "https://www.reuters.com/article/brief-protalix-announces-positive-result/brief-protalix-announces-positive-results-from-phase-ii-clinical-trial-of-oprx-106-for-treatment-of-ulcerative-colitis-idUSASC09RYF", "ord_in_thread": 0, "title": "BRIEF-Protalix Announces Positive Results From Phase II Clinical Trial Of OPRX-106 For Treatment Of Ulcerative Colitis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "min read   protalix biotherapeutics inc", "sentiment": "none"}, {"name": "treatment of ulcerative colitis reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "  in 7 minutes BRIEF-Protalix Announces Positive Results From Phase II Clinical Trial Of OPRX-106 For Treatment Of Ulcerative Colitis Reuters Staff 1 Min Read   Protalix Biotherapeutics Inc: * PROTALIX BIOTHERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE II CLINICAL TRIAL OF OPRX-106 FOR THE TREATMENT OF ULCERATIVE COLITIS * PROTALIX BIOTHERAPEUTICS INC - KEY EFFICACY ENDPOINTS OF STUDY WERE MET * PROTALIX BIOTHERAPEUTICS INC - OPRX-106 WAS SAFE AND WELL TOLERATED WITH ONLY MILD TO MODERATE ADVERSE EVENTS IN STUDY * PROTALIX BIOTHERAPEUTICS INC - NO ANTI-DRUG ANTIBODIES WERE DETECTED IN STUDY  ", "external_links": [], "published": "2018-03-13T13:11:00.000+02:00", "crawled": "2018-03-13T13:21:23.013+02:00", "highlightTitle": ""}